San-Diego-primarily based Health-related Marijuana Inc. has announced that its investment firm, AXIM Biotechnologies (AXIM) has entered into a service agreement with the contract investigation organization, QPS Netherlands BV (QPS) to commence conducting comparison research on chewing gum created with all-natural cannabidiol ( CBD) and synthesized THC (dronabinol).
Also identified as Marinol or Syndros, dronabinol is a type of synthetic THC that at present resides in the Schedule III category in the United States.
QPS will be conducting two open-label single-dose research followed by a randomized, double-blind study involving many doses. The tests will be made use of to gauge the bioavailability of dronabinol in MedChew, a solution intended for the therapy of nausea and vomiting in cancer and AIDS sufferers.
“We appear forward to continuing our assistance for AXIM as they conduct these research and stay optimistic about the company’s future final results,” mentioned Health-related Marijuana Inc. CEO Dr. Stuart Titus. “It is pretty vital for us to be capable to prove the efficacy and security of our goods and it is wonderful to see that two of AXIM’s created goods will be tested in these upcoming research.”
AXIM CEO John Huellmoeller mentioned that the agreement is an vital step in their clinical improvement system as they are functioning via several trial stages so they can bring their goods to suffering sufferers.
“We are proud to function with a nicely-respected firm such as QPS Netherlands that shares our commitment to excellence to bring nicely-tested and confirmed drugs to marketplace,” mentioned Huellmoeller.
QPS will also conduct an open-label, randomized, 3-period pharmacokinetic study on AXIM’s CanChew solution which is developed for the therapy of symptoms of drug-connected psychosis.